RMD

ResMed Inc

NYSE: RMD · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES

$198.76

+0.89% today

Updated 2026-06-05

Market cap

$28.25B

P/E ratio

18.80

P/S ratio

5.10x

EPS (TTM)

$10.36

Dividend yield

1.21%

52W range

$180 – $292

Volume

1.4M

Market cap

$28.25B

P/E ratio

18.80

P/S ratio

5.10x

EPS (TTM)

$10.36

Dividend yield

1.21%

52W range

$180 – $292

Volume

1.4M

ResMed Inc (RMD) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

RMD · ResMed Inc · Price target summary

Current

$198.76

Consensus

$293.70

+47.77%

2030 Target

$627.45

+215.68%

DCF

$204.63

-26.87% MoS

Current price

$198.76

Analyst consensus

$293.70

+47.77%

2030 Target

$627.45

+215.68%

Intrinsic (DCF)

$204.63

-26.87% MoS

10 analysts:

5 Buy4 Hold1 Sell

Management guidance

No specific CEO revenue targets disclosed in available data. Management has guided to 10.58% revenue growth for FY2026 ($5.69B) and 7.38% growth for FY2027 ($6.11B) based on analyst consensus. Company maintains strong organic growth trajectory with digital health expansion and international market opportunities.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

RMD · ResMed Inc · Revenue & price projection · 2023–2030E

Actual revenue Projected revenue Base case Bull to bear range

Bear case (2030)

$403.36

$7.5B Rev × 8x P/S

Base case (2030)

$627.45

$7.5B Rev × 12x P/S

Bull case (2030)

$1,030.81

$7.5B Rev × 20x P/S

WallStSmart.com

Financial forecast — research-backed

Metric	2025	2026 (E)	2027 (E)	2028 (E)	2029 (E)	2030 (E)
Revenue	$5.1B	$5.7B	$6.1B	$6.6B	$7.0B	$7.5B
Revenue growth	9.8%	10.6%	7.4%	7.3%	7.0%	6.8%
EPS	$5.36	$11.12	$12.28	$13.50	$14.75	$16.10
P/S ratio	—	12.0x	12.0x	12.0x	12.0x	12.0x
Implied price	—	$470.59	$493.00	$537.82	$582.63	$627.45

RMD · ResMed Inc · Catalysts & risks

Growth catalysts

+ Digital health and cloud-based software expansion driving recurring revenue

+ International market penetration offsetting U.S. sleep apnea demand normalization

+ Innovation in mask technology and respiratory care devices

+ Aging population and chronic disease prevalence supporting long-term demand

Key risks

- GLP-1 weight-loss drug adoption reducing obesity-related sleep apnea cases

- Insurance reimbursement pressure and competitive intensity

- U.S. CPAP device market saturation and slowing demand growth

- Execution risk on digital health strategy and international expansion

Methodology

ResMed Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 10 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.